Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT05413122

Evaluating Smoking Cessation Interventions for PWH in South Africa

Led by Johns Hopkins University · Updated on 2025-06-27

660

Participants Needed

1

Research Sites

196 weeks

Total Duration

On this page

Sponsors

J

Johns Hopkins University

Lead Sponsor

C

Colorado State University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.

CONDITIONS

Official Title

Evaluating Smoking Cessation Interventions for PWH in South Africa

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Attend one of the selected study clinics
  • Have a confirmed HIV diagnosis with evidence such as ART prescription or current ART medication pack
  • Have been taking antiretroviral therapy for at least three consecutive months
  • Are current tobacco smokers who have smoked at least 100 cigarettes in their lifetime, smoke daily for the past 30 days, have exhaled breath carbon monoxide of 7 ppm or more, and a positive urine cotinine test
  • Own or have household access to a mobile phone
  • Provide written informed consent
Not Eligible

You will not qualify if you...

  • Currently receiving smoking cessation counseling or medication within the past 14 days
  • Unable to participate due to severe medical illness (Karnofsky score 40 or less)
  • History of seizures, cancer, heart disease, stroke, myocardial infarction, stomach ulcers, kidney failure, or liver failure
  • Have generalized eczema or psoriasis
  • Cognitive dysfunction or psychosis as defined by the Mini-International Neuropsychiatric Interview
  • Suicide risk as defined by the Columbia-Suicide Severity Rating Scale
  • Pregnant, planning pregnancy within 4 months, lactating, or unwilling to use effective birth control
  • History of adverse reactions to varenicline or nicotine patches
  • Not planning to continue care at the clinic for the next 52 weeks
  • Deemed unsuitable by the attending investigator for the clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Perinatal HIV Research Unit (PHRU)

Soweto, Gauteng, South Africa

Actively Recruiting

Loading map...

Research Team

J

Jonathan E Golub, PhD MPH

CONTACT

L

Laura Steiner, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

TREATMENT

Number of Arms

16

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluating Smoking Cessation Interventions for PWH in South Africa | DecenTrialz